Fuzheng Huayu capsules reducing development of hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B based on the ratio of neutrophils/lymphocytes
10.3760/cma.j.cn501113-20230620-00268
- VernacularTitle:基于中性粒细胞/淋巴细胞比值探讨扶正化瘀胶囊降低乙型肝炎肝硬化患者肝细胞癌的发生率
- Author:
Ke SHI
1
;
Jie HOU
;
Yi ZHANG
;
Yufei BI
;
Xianbo WANG
Author Information
1. 首都医科大学附属北京地坛医院中西医结合中心，北京 100015
- Keywords:
Cirrhosis;
Hepatocellular carcinoma;
Anti-liver fibrosis treatment;
Neutrophil-lymphocyte ratio
- From:
Chinese Journal of Hepatology
2023;31(9):969-973
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the advantage of Fuzheng Huayu capsule in patients with hepatitis B cirrhosis based on neutrophil/lymphocyte ratio (NLR) risk stratification in reducing the incidence of hepatocellular carcinoma (HCC).Methods:916 cases diagnosed with hepatitis B cirrhosis and followed up for five years from January 2011 to January 2016 at Beijing Ditan Hospital Affiliated with Capital Medical University were included, and clinical data were collected. Patients were divided into a combination group and an antiviral group according to whether they were treated with anti-fibrosis for≥6 months. The antiviral group was treated with entecavir or tenofovir disoproxil, while the combination group was treated with Fuzheng Huayu capsules based on the antiviral therapy. The incidence of HCC was compared between the two groups of patients within five years. The advantaged groups treated with Fuzheng Huayu capsule were explored based on NLR risk stratification. The independent sample t-test and Mann-Whitney U test were used to compare measurement data between two groups. Categorical variable data were compared using either the χ2 test or Fisher's exact probability method. The incidence of HCC in the two groups of patients was analyzed through the Kalplan-Merier curve and compared using the log-rank method. Results:There were 299 (32.6%) and 617 (67.4%) cases in the combined group and the antiviral group, respectively. A total of 154 (16.8%) patients developed HCC during the follow-up period. The five-year cumulative incidence of HCC in the combination group was lower than that in the antiviral group (10.7% vs. 19.8%, χ2 = 11.848, P = 0.000 4). Patients with baseline NLR>3 had an increased risk of HCC. According to NLR risk stratification, there were 191 cases in the low-risk group (NLR<1.4), 462 cases in the medium-risk group (NLR1.4 ~ 3.0), and 263 cases in the high-risk group (NLR>3). Among medium to high-risk patients, the incidence of HCC was significantly reduced in the combination group (11.5% vs. 19.4%, χ2 = 4.519, P = 0.029; 13.2% vs. 26.2%, χ2 = 5.258, P = 0.019), while there was no statistically significant difference in the incidence of HCC among the low-risk group ( P = 0.38). Conclusion:Compared with antiviral treatment alone, Fuzheng Huayu capsules combined with antiviral treatment can better reduce the five-year HCC incidence rate in patients with hepatitis B cirrhosis. Medium-and high-risk patients with NLR stratification are the most advantageous population to be treated with Fuzheng Huayu capsules.
